Trial Profile
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Androgen-independent Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Patupilone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Feb 2017 Status changed from suspended to completed.
- 26 Apr 2014 New trial record